Axonics Stock Fair Value Calculator – Two Sigma Investments LP Adds Axonics, to Portfolio in 2023.
March 19, 2023
Trending News 🌥️
In 2023, Two Sigma Investments LP made the decision to add Axonics ($NASDAQ:AXNX), Inc. to their portfolio. The investment, which was disclosed in the firm’s filing with the Securities and Exchange Commission, marked a major milestone for Axonics, Inc., as it opened up new opportunities for the company. Axonics, Inc. is a medical technology company that specializes in developing and manufacturing neuromodulation devices for the treatment of various conditions. Their decision to invest in Axonics highlights the trust they have in the company to continue producing successful products.
By investing in Axonics, Two Sigma is setting themselves up for long-term growth and potential profits. This news has been met with enthusiasm within the medical technology space as Axonics is seen as a leader in the industry. With this additional investment, Axonics, Inc. will be able to continue developing innovative solutions to help improve patient outcomes and revolutionize the way healthcare is delivered.
The media exposure of Axonics has been mostly positive till now. On Wednesday, the stock of AXONICS opened at $51.9 and closed at $53.4, up by 0.9% from previous closing price of 53.0. The stock made steady gains in value throughout the day, demonstrating investors’ growing confidence in the company. This addition to the portfolio is likely to be beneficial to both Two Sigma and Axonics as they move forward. Live Quote…
About the Company
Below shows the total revenue, net income and net margin for Axonics. More…
|Total Revenues||Net Income||Net Margin|
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Axonics. More…
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Axonics. More…
|Total Assets||Total Liabilities||Book Value Per Share|
Key Ratios Snapshot
Some of the financial key ratios for Axonics are shown below. More…
|3Y Rev Growth||3Y Operating Profit Growth||Operating Margin|
Analysis – Axonics Stock Fair Value Calculator
After analyzing AXONICS‘s fundamentals, GoodWhale has conducted an in-depth assessment. Our proprietary Valuation Line indicates that the fair value of AXONICS’s shares is around $87.3. This means that currently AXONICS stock is traded at $53.4, which implies an undervaluation of 38.9%. We believe this presents an attractive investment opportunity for those looking to add this stock to their portfolio. More…
The company’s products include the Axonics r-SNM System, a sacral neuromodulation system that is used to treat urinary incontinence and bowel dysfunction; and the Axonics Sacral Neuromodulation System, a rechargeable neuromodulation system that is used to treat urinary incontinence, bowel dysfunction, and sacral pain. Alphatec Holdings Inc, Xtant Medical Holdings Inc, INVO Bioscience Inc are all companies that compete with Axonics Inc.
– Alphatec Holdings Inc ($NASDAQ:ATEC)
Alphatec Holdings, Inc. is a medical device company that designs, develops, manufactures and markets spine products for the surgical treatment of spinal disorders associated with degenerative disc disease and trauma. The company’s product offerings include a broad range of minimally invasive and stand-alone products used in spine surgery. Alphatec’s core products consist of facet fixation systems, interbody fusion cages, thoracolumbar fixation systems, and related instrumentation. The company also offers a line of biologics products. Alphatec has a market cap of 1.07B as of 2022 and a return on equity of -374.34%.
– Xtant Medical Holdings Inc ($NYSEAM:XTNT)
Xtant Medical Holdings Inc is a medical device company that develops, manufactures, and markets regenerative medicine products and medical devices for the orthopedic, spine, and sports medicine markets worldwide.
The company has a market cap of $68.18 million and a return on equity of -14.12%. Xtant Medical Holdings Inc develops, manufactures, and markets regenerative medicine products and medical devices for the orthopedic, spine, and sports medicine markets worldwide.
– INVO Bioscience Inc ($NASDAQ:INVO)
Invo Bioscience is a biotech company that focuses on developing and commercializing in vitro fertilization (IVF) products. The company’s products are used by fertility clinics to improve IVF success rates and reduce the costs associated with fertility treatments.
Invo Bioscience has a market cap of $14 million and a return on equity of -107.22%. The company’s products are used by fertility clinics to improve IVF success rates and reduce the costs associated with fertility treatments.
Axonics, Inc. is a medical technology company that has recently been added to the portfolio of Two Sigma Investments LP in 2023. Media exposure for Axonics has been mostly positive, indicating a growing investor interest. Analysts have noted that Axonics has been successful in developing advanced implantable neuromodulation devices to treat bladder and bowel dysfunction, as well as other conditions. These devices provide an alternative to current treatments and have been met with positive reviews from both medical professionals and patients.
The company’s revenue has also grown significantly since its inception, and its stock is currently trading at an all-time high. As such, analysts expect Axonics to be a strong investment in the short and long-term. With its innovative technologies and promising revenue growth, Axonics may offer significant potential for investors.
Leave a Comment